Janux Therapeutics, Inc. (JANX) Total liabilities 2020–2025
Janux Therapeutics, Inc. (JANX) total liabilities at each fiscal year-end, per SEC filings.
$44.7MFY2025 · since FY2020: $9.2M → $44.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $44.7M | +15.5% |
| FY2024 | $38.7M | +7.4% |
| FY2023 | $36.1M | -16.7% |
| FY2022 | $43.3M | +220.6% |
| FY2021 | $13.5M | +46.2% |
| FY2020 | $9.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More JANX financial trends
JANX RevenueJANX Net incomeJANX Net marginJANX Gross profitJANX Gross marginJANX Operating incomeJANX Operating marginJANX Operating cash flowJANX Free cash flowJANX Capital expendituresJANX Return on equityJANX Stock buybacksJANX Dividends paidJANX Total assetsJANX Shareholders’ equityJANX overview →